ANX009

About annexon-biosciences

Annexon Biosciences is developing first-in-class C1q inhibitors to halt the classical complement pathway, a key driver of tissue damage in severe diseases of the body, brain, and eye. Founded on groundbreaking research from Stanford, the company has built a versatile platform with multiple drug candidates in late-stage clinical trials, including ANX005 for GBS and ANX007 for geographic atrophy. Its strategy focuses on achieving functional clinical benefits in areas of high unmet need, positioning it as a leader in upstream complement inhibition with significant near-term catalysts.

Therapeutic Areas